๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase I Clinical Studies of the Advanced Glycation End-product (AGE)-Breaker TRC4186

โœ Scribed by Kumar P. Chandra, Ajay Shiwalkar, Jignesh Kotecha, Purav Thakkar, Ambrish Srivastava, Vijay Chauthaiwale, Sanjay K. Sharma, Maurice R. Cross, Dr Chaitanya Dutt

Book ID
119930591
Publisher
Springer International Publishing AG
Year
2009
Tongue
English
Weight
221 KB
Volume
29
Category
Article
ISSN
1179-1918

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

The cross-link breaker, N-phenacylthiazo
The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation
โœ Cooper, M. E.; Thallas, V.; Forbes, J.; Scalbert, E.; Sastra, S.; Darby, I.; Sou ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› Springer ๐ŸŒ English โš– 250 KB

## Aims/hypothesis: Advanced glycation is postulated to have a pivotal role in mediating diabetic vascular complications. the emergence of thiazolium compounds such as n-phenacylthiazolium bromide which cleave preformed advanced glycation end products (ages) has allowed us to explore the effects of

Differences in the modulating potential
Differences in the modulating potential of advanced glycation end product (AGE) peptides versus AGE proteins
โœ Deuther-Conrad, Winnie; Franke, Sybille; Sommer, Manfred; Henle, Thomas; Stein, ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› Nature Publishing Group ๐ŸŒ English โš– 625 KB

Differences in the modulating potential of advanced glycation end product (AGE) peptides versus AGE proteins. Advanced glycation end products (AGEs), identified as irreversible products of a complex reaction of carbonyl groups of reducing sugars with free protein amino groups, are characterized by r